306 related articles for article (PubMed ID: 29909472)
1. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
Said MA; Mehta A
Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
[TBL] [Abstract][Full Text] [Related]
2. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
3. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML
J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115
[TBL] [Abstract][Full Text] [Related]
4. Persistent sexual side effects of finasteride for male pattern hair loss.
Irwig MS; Kolukula S
J Sex Med; 2011 Jun; 8(6):1747-53. PubMed ID: 21418145
[TBL] [Abstract][Full Text] [Related]
5. 5α-Reductase inhibitors in androgenetic alopecia.
Yim E; Nole KL; Tosti A
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
7. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
8. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
Lauck KC; Limmer A; Harris P; Kivelevitch D
J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
[No Abstract] [Full Text] [Related]
9. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
10. Persistent sexual side effects of finasteride: could they be permanent?
Irwig MS
J Sex Med; 2012 Nov; 9(11):2927-32. PubMed ID: 22789024
[TBL] [Abstract][Full Text] [Related]
11. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
Seale LR; Eglini AN; McMichael AJ
J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
[TBL] [Abstract][Full Text] [Related]
12. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.
Ganzer CA; Jacobs AR; Iqbal F
Am J Mens Health; 2015 May; 9(3):222-8. PubMed ID: 24928450
[TBL] [Abstract][Full Text] [Related]
13. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
[TBL] [Abstract][Full Text] [Related]
15. 5-alpha reductase inhibitors and erectile dysfunction: the connection.
Erdemir F; Harbin A; Hellstrom WJ
J Sex Med; 2008 Dec; 5(12):2917-24. PubMed ID: 19090946
[TBL] [Abstract][Full Text] [Related]
16. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
[TBL] [Abstract][Full Text] [Related]
19. Prostate, baldness drugs linked to sexual dysfunction.
Kuehn BM
JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
[No Abstract] [Full Text] [Related]
20. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
